Brunswick educators, land trust partner to revamp science curriculum
Kate Furbish and Harriet Beecher Stowe Elementary Schools rolled out the new units in K-5 classrooms throughout the school year. Kids are doing "big, messy experiments" — as fifth grade HBS teacher Kate Kovach describes — digging in the garden, hunting for decomposers in the woods, tracking the sun's path and more.
Lesson plans were designed over two years by BTLT's Cathance River Education Alliance and a team of BSD teachers to align with guidelines in the recently adopted Next Generation Science Standards (NGSS) — which focus on actually doing science, rather than memorization.
"Elementary teachers usually don't receive much extra training in science teaching; science kind of gets overlooked sometimes," said Sarah Rodgers, director of education for the land trust and education alliance. "As they were trying to figure out how to incorporate new federal science standards, they turned to us."
The land trust partnered with Topsham-based Maine School Administrative District 75 a few years ago on a similar curriculum program, Rodgers said.
BTLT educators provided teachers with ready-made experiment kits for each unit and cohesive guidelines on how to get students engaged in learning — by making claims, gathering evidence and drawing conclusions.
"When they find evidence to support or refute their claim, they're building their own knowledge," Kovach said.
Kovach's fifth graders got outside this school year to learn about cycles of matter in the ecosystem. Their experiments included making compost piles for the school garden and putting together terrariums. She said students have been so engaged in class that they're bringing science home.
"I had kids bringing in photos of mycelium [fungus root structures] from when they were outside playing in the woods," Kovach said. "Or we're out in the playground and they hand me a rock and say, 'Here's some geosphere for you.'"
"They're learning about the world they're living in now," Kovach added.
Third graders harvest bean plants in the fall to learn about different traits and save the seed to plant in the spring — observing the life cycle in real time.
"When they come back in fourth grade, they know the incoming third graders will start their year by harvesting the beans," Rodgers said.
It's all about "taking the lesson out of a book and putting it in their hands," Rodgers said. "If you just learn about the life cycle in a book or diagram, it's not that exciting."
Kate Furbish second-grade teacher Meredith Sciacca said the new curriculum has helped her kids "grow as students and learners."
"Aligning our science curriculum with NGSS standards specifically through a local lens has greatly improved our ability to deliver quality science instruction that is directly connected to our students' lives," Sciacca said in an email.
Copy the Story Link
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Scientists tout potential weight loss advance using gene technology
There could be new hope for people aiming to fight obesity following a research breakthrough identifying certain microproteins that store fat. In findings published in the Proceedings of the National Academy of Sciences (PNAS) in the US, the team from the California-based Salk Institute for Biological Studies said that the microproteins "could potentially serve as drug targets to treat obesity and other metabolic disorders." The findings could prove particularly useful for people who struggle with other treatments such as lifestyle changes, bariatric surgery or courses of drugs such as Ozempic and Wegovy. "The obesity rate has more than doubled in the last 30 years, affecting more than one billion people worldwide," the Salk Institute warned, reminding that being overweight is linked to "other metabolic disorders" such as diabetes, cardiovascular diseases, chronic kidney disease, and cancers. Microproteins, according to the team, are "an understudied class of molecules found throughout the body that play roles in both health and disease." The team believes the findings are noteworthy because they entailed the use of CRISPR gene editing to screen thousands of fat cell genes to try to find genes "that likely code for microproteins that regulate either fat cell proliferation or lipid accumulation." "We wanted to know if there was anything we had been missing in all these years of research into the body's metabolic processes," says Salk's Victor Pai. Solve the daily Crossword
Boston Globe
a day ago
- Boston Globe
Biogen sees potential in combining Alzheimer's and obesity drugs
Advertisement Biogen's looking to the growth of its Alzheimer's drug Leqembi to offset the decline of its multiple sclerosis franchise, which is facing competition from cheaper generic drugs. Biogen's new Alzheimer's drug is already facing competition from Eli Lilly & Co.'s Alzheimer's drug, which was approved in the US last year and has since captured around 30 percent of the market, according to analysts. Other companies are also circling. Novo is carrying out clinical trials to assess whether the main ingredient in diabetes drug Ozempic and weight-loss shot Wegovy might help people with early Alzheimer's disease. Research suggests that the weight-loss drug could slow Alzheimer's progression by impacting inflammation and vascular health. Results of Novo's late-stage trial are expected later this year. Advertisement Viehbacher noted that being overweight is a risk factor for Alzheimer's. He cautioned the Novo study 'is a fairly risky proposition,' adding that 'most of the experts we're talking to are not convinced that it will work.' 'It's logical if you have a weight-loss drug that you can see some benefit, but it's actually pretty hard to move the needle on the cognitive side,' Viehbacher added. Alzheimer's drug development has been riddled with failures, even when drugs looked promising in early studies. Leqembi is a partnership between Cambridge, Massachusetts-based Biogen and Japanese drugmaker Eisai Co. Biogen makes the active ingredient for Leqembi in Switzerland. The company then ships it to North Carolina, where it gets made into a product. President Donald Trump recently put a 39 percent tariff on imports from Switzerland. It's unclear whether this would impact Biogen's drug. Still, Viehbacher said the company has the ability to start producing the substance used to make Leqembi in North Carolina for the US market, while continuing to make it in Switzerland for outside the US. He said the company always intended to use its North Carolina facilities to make Leqembi and the potential move was not a direct response to Trump's tariff threats. Last month, Biogen announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park.
Geek Wire
a day ago
- Geek Wire
Ai2 unveils MolmoAct: Open-source robotics system reasons in 3D and adjusts on the fly
Jiafei Duan, Ai2 researcher, shows MolmoAct controlling a robotic arm. (GeekWire Photo / Todd Bishop) The Allen Institute for AI released a new AI robotics system that uses novel approaches to help robots navigate messy real-world environments, while making all of the model's code, data, and training methods publicly available under open-source principles. The system, called MolmoAct, converts 2D images into 3D visualizations, previews its movements before acting, and lets human operators adjust those actions in real time. It differs from existing robotics models that often work as opaque black boxes, trained on proprietary datasets. Ai2 expects the system to be used by robotics researchers, companies, and developers as a foundation for building robots that can operate in unstructured environments such as homes, warehouses, and disaster response scenes. In demos last week at Ai2's new headquarters north of Seattle's Lake Union, researchers showed MolmoAct interpreting natural language commands to direct a robotic arm to pick up household objects, such as cups and plush toys, and move them to specific locations. Researchers described it as part of AI2's broader efforts to create a comprehensive set of open-source AI tools and technologies. The Seattle-based research institute was founded in 2014 by the late Microsoft co-founder Paul Allen, and is funded in part by his estate. Ai2's flagship OLMo large language model is a fully transparent alternative to proprietary systems, with openly available training data, code, and model weights, designed to support research and public accountability in AI development. The institute's projects are moving in 'one big direction' — toward a unified AI model 'that can do reasoning and language, that can understand images, videos, that can control a robot, and that can make sense of space and actions,' said Ranjay Krishna, Ai2's research lead for computer vision, and a University of Washington Allen School assistant professor. MolmoAct builds on AI2's Molmo multimodal AI model — which can understand and describe images — by adding the ability to reason in 3D and direct robot actions.
